Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein

Cancer Research

Volumn 73, Issue 1, 2013, Pages 139-149

  Ochoa, Maria C ^a   Fioravanti, Jessica ^a   Rodriguez, Inmaculada ^a   Hervas Stubbs, Sandra ^a   Azpilikueta, Arantza ^a   Mazzolini, Guillermo ^c   Guŕpide, Alfonso ^a   Prieto, Jesus ^a   Pardo, Julian ^b   Berraondo, Pedro ^a   Melero, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GRANZYME A; GRANZYME B; HIGH DENSITY LIPOPROTEIN; HYBRID PROTEIN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; RECOMBINANT PROTEIN; RECOMBINANT SUSHI INTEREUKIN 15 APOLIPOPROTEIN A1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; GENE TRANSFER; LIVER; LIVER METASTASIS; LUNG; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN; T LYMPHOCYTE; TREATMENT RESPONSE;

ANIMALS; APOLIPOPROTEIN A-I; CD8-POSITIVE T-LYMPHOCYTES; CHOLESTEROL, HDL; GENE TRANSFER TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PLASMIDS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84871947763     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2660     Document Type: Article

References (25)

1. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010;16:6019-28.
2. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44 high T cells and its antitumor action. J Immunol 2008;180:2099-106.
3. de Jong JL, Farner NL, Sondel PM. Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits. Cytokine 1998;10:920-30.
4. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 2009;106:19455-60.
5. Kukita T, Arima N, Matsushita K, Arimura K, Ohtsubo H, Sakaki Y, et al. Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15. Br J Haematol 2002;119:467-74.
6. Yu YL, Wei CW, Chen YL, Chen MH, Yiang GT. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. Int J Oncol 2010;36:365-70.
7. Vera M, Razquin N, Prieto J, Melero I, Fortes P, Gonzalez-Aseguinolaza G. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther 2005;12:950-9.
8. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67:4940-8.
9. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006;281:1612-9.
10. Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009;8:2736-45.
11. Francis GA. The complexity of HDL. Biochim Biophys Acta 2010;1801:1286-93.
12. Fioravanti J, Gonzalez I, Medina-Echeverz J, Larrea E, Ardaiz N, Gonzalez-Aseguinolaza G, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 2011;53:1864-73.
13. Pardo J, Balkow S, Anel A, Simon MM. Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol 2002;32:2881-7.
14. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 1999;162:6671-80.
15. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999;6:1779-84.
16. Soman G, Yang X, Jiang H, Giardina S, Vyas V, Mitra G, et al. MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 2009;348:83-94.
17. Hervas-Stubbs S, Mancheno U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, et al. CD8 T cell priming in the presence of IFN-alpha renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol 2012;189:3299-310.
18. He Y, Pimenov AA, Nayak JV, Plowey J, Falo LD Jr, Huang L. Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther 2000;11:547-54.
19. Lodolce JP, Burkett PR, Boone DL, Chien M, Ma A. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med 2001;194:1187-94.
20. Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, et al. IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A 2011;108:6217-22.
21. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer andmemory phenotype CD8+ T cells. J Exp Med 2001;193:219-31.
22. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000;97:11445-50.
23. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010;107:19997-20002.
24. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68.
25. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in Rhesus macaques. Blood 2011;117:4787-95.